SI1773999T1 - Cepivo za preprečevanje in zdravljenje HIV-infekcije - Google Patents

Cepivo za preprečevanje in zdravljenje HIV-infekcije

Info

Publication number
SI1773999T1
SI1773999T1 SI200530868T SI200530868T SI1773999T1 SI 1773999 T1 SI1773999 T1 SI 1773999T1 SI 200530868 T SI200530868 T SI 200530868T SI 200530868 T SI200530868 T SI 200530868T SI 1773999 T1 SI1773999 T1 SI 1773999T1
Authority
SI
Slovenia
Prior art keywords
vaccine
hiv
infection
prevention
treatment
Prior art date
Application number
SI200530868T
Other languages
English (en)
Inventor
Helge Abrecht
Martine Delchambre
Martine Marchand
Nathalie Louise Mathy
Philippe Jean Gervais Ghislain Permanne
Gerald Hermann Voss
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of SI1773999T1 publication Critical patent/SI1773999T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SI200530868T 2004-08-05 2005-08-03 Cepivo za preprečevanje in zdravljenje HIV-infekcije SI1773999T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0417494.2A GB0417494D0 (en) 2004-08-05 2004-08-05 Vaccine
EP05769948A EP1773999B1 (en) 2004-08-05 2005-08-03 Vaccine for prevention and treatment of hiv-infection

Publications (1)

Publication Number Publication Date
SI1773999T1 true SI1773999T1 (sl) 2010-01-29

Family

ID=32982606

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200530868T SI1773999T1 (sl) 2004-08-05 2005-08-03 Cepivo za preprečevanje in zdravljenje HIV-infekcije

Country Status (32)

Country Link
US (2) US7612173B2 (sl)
EP (3) EP2130921B1 (sl)
JP (3) JP2008507987A (sl)
KR (1) KR101501495B1 (sl)
CN (2) CN101035897B (sl)
AR (2) AR050102A1 (sl)
AT (1) ATE443769T1 (sl)
AU (1) AU2005268856B2 (sl)
BR (1) BRPI0514108A (sl)
CA (1) CA2575898C (sl)
CY (1) CY1109667T1 (sl)
DE (1) DE602005016810D1 (sl)
DK (1) DK1773999T3 (sl)
ES (3) ES2334044T3 (sl)
GB (1) GB0417494D0 (sl)
HK (1) HK1108168A1 (sl)
HR (1) HRP20090678T1 (sl)
IL (2) IL180947A0 (sl)
MA (1) MA28983B1 (sl)
MX (1) MX2007001515A (sl)
MY (1) MY145614A (sl)
NO (1) NO20070988L (sl)
NZ (1) NZ552976A (sl)
PE (1) PE20060577A1 (sl)
PL (1) PL1773999T3 (sl)
PT (1) PT1773999E (sl)
RU (1) RU2441878C2 (sl)
SG (1) SG155206A1 (sl)
SI (1) SI1773999T1 (sl)
TW (1) TWI365191B (sl)
WO (1) WO2006013106A2 (sl)
ZA (1) ZA200700771B (sl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
JP4838936B2 (ja) * 1998-10-23 2011-12-14 イデア アクチェンゲゼルシャフト 装荷量を改善しおよび脱／会合速度を制御可能とするための、巨大分子と複合凝集体との会合体を開発し、テストし、かつ利用する方法
SI1031347T1 (sl) 1999-01-27 2002-10-31 Idea Ag Transnazalni transport/imunizacija (cepljenje) z visoko-adaptivnimi nosilci
ES2173678T3 (es) 1999-01-27 2002-10-16 Idea Ag Vacunacion no invasiva a traves de la piel.
AU5409699A (en) * 1999-07-05 2001-01-22 Idea Ag A method for the improvement of transport across adaptable semi-permeable barriers
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
EP1811961A2 (en) * 2004-11-12 2007-08-01 Idea Ag Extended surface aggregates in the treatment of skin conditions
US20090208515A1 (en) * 2005-05-12 2009-08-20 Peter Franz Ertl Vaccine composition
AU2006252406B2 (en) 2005-06-01 2012-05-17 California Institute Of Technology Method of targeted gene delivery using viral vectors
EP2013227A4 (en) * 2006-05-09 2010-07-28 Jackson H M Found Military Med ANTI-HIV-1 IMMUNOGENIC COMPOSITIONS
WO2008011636A2 (en) * 2006-07-21 2008-01-24 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
SI2137210T1 (sl) * 2007-03-02 2017-01-31 Glaxosmithkline Biologicals S.A. Nov postopek in sestavki
US20110244496A1 (en) * 2007-03-06 2011-10-06 Rutgers, The State University Hiv reverse transcriptase compositions and methods
EP2142212A2 (en) * 2007-03-26 2010-01-13 International Aids Vaccine Initiative Method of elicting immune response with a modified mva viral hiv-1 vector
AR066676A1 (es) 2007-05-24 2009-09-02 Glaxosmithkline Biolog Sa Composicion antigenica liofilizada que contiene un agonista del receptor tipo toll
CA2708718A1 (en) * 2007-12-21 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccine
KR101548143B1 (ko) * 2008-07-16 2015-08-28 베일러 리서치 인스티튜트 극대화된 Ｇａｇ 및 Ｎｅｆ를 수지상 세포에 표적화시킴을 기본으로 하는 ＨＩＶ 백신
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
AP2857A (en) 2008-09-09 2014-02-28 Celebrity Biogens Llc Bioactive composition for the treatment of the HIV/AIDS, method for manufacturing and using the same
EP2456786B2 (en) 2009-07-24 2017-04-19 Immune Design Corp Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
EP2552480A1 (en) * 2010-03-26 2013-02-06 GlaxoSmithKline Biologicals S.A. Hiv vaccine
MX340739B (es) 2010-05-14 2016-07-22 Brookhaven Science Ass Llc Quimeras ospa y su uso en vacunas.
WO2012041842A1 (en) * 2010-09-27 2012-04-05 Glaxosmithkline Biologicals S.A. Vaccine
JP2012120506A (ja) * 2010-12-10 2012-06-28 Tosoh Corp Ａｍｖ逆転写酵素遺伝子、該遺伝子によりコードされるａｍｖ逆転写酵素及び該遺伝子を用いるａｍｖ逆転写酵素の製造方法
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
JP2013146235A (ja) * 2012-01-20 2013-08-01 Tosoh Corp トリ骨髄芽細胞腫ウイルス逆転写酵素の製造方法
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
ES2707288T3 (es) 2012-03-30 2019-04-03 Immune Design Corp Partículas de vectores lentivíricos que tienen eficiencia de transducción mejorada para células que expresan DC-SIGN
WO2014160747A2 (en) 2013-03-26 2014-10-02 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
TWI806081B (zh) 2014-07-11 2023-06-21 美商基利科學股份有限公司 用於治療HIV之toll樣受體調節劑
KR102014518B1 (ko) 2017-01-05 2019-08-26 서울대학교산학협력단 HIV 1의 p24 단백질을 발현하는 벡터가 도입된 재조합 마이코박테리움 스메그마티스 균주 및 이를 포함하는 백신
GB201812647D0 (en) 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
US11795210B2 (en) 2019-07-16 2023-10-24 Gilead Sciences, Inc. HIV vaccines and methods of making and using
CA3161633A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines
WO2021195286A1 (en) 2020-03-27 2021-09-30 Svenska Vaccinfabriken Produktion Ab Compositions and methods for treating and preventing coronaviruses
TW202330575A (zh) 2021-09-29 2023-08-01 瑞典商斯文斯卡疫苗生產股份有限公司 用於治療及預防冠狀病毒之組成物及方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DE3300234A1 (de) 1983-01-05 1984-07-05 Display-Design GmbH für moderne Verkaufsförderungsmittel und Raumaussstattung, 6233 Kelkheim Etagenturm zur warenausstellung
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
DK643188A (da) * 1987-11-24 1989-05-25 Smithkline Biolog Ekspression af hiv-proteiner i e.coli og s.cerevisiae
US5221610A (en) 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
KR0172970B1 (ko) 1992-06-17 1999-02-01 김영길 Aids백신에 유용한 키메릭 단백 및 그의 제조방법
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
US5962635A (en) 1993-05-18 1999-10-05 Biomolecular Research Institute Ltd. Therapeutic compounds
WO1995014026A1 (en) 1993-11-17 1995-05-26 Laboratoires Om S.A. Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
EP1537877A3 (en) 1996-10-11 2005-08-03 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
ES2500490T3 (es) 1997-08-29 2014-09-30 Antigenics Inc. Composiciones que comprenden el adyuvante QS-21 y polisorbato o ciclodextrina como excipiente
JP4426091B2 (ja) 1997-09-05 2010-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニンを含有する水中油型エマルション
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
WO2000007631A1 (en) 1998-08-04 2000-02-17 The Henry M. Jackson Foundation Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response
CA2393861A1 (en) 1999-12-17 2001-06-21 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
DK1240186T3 (da) * 1999-12-23 2010-05-31 Medical Res Council Forbedringer i eller relateret til immunrespons mod HIV
US20020155127A1 (en) * 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
WO2002022080A2 (en) 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
CU23235A1 (es) 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
EP1434859A2 (en) * 2001-07-25 2004-07-07 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
MXPA04002631A (es) * 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
NZ550416A (en) 2001-11-21 2008-06-30 Univ Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
US20030134404A1 (en) 2001-11-26 2003-07-17 Lochrie Michael A. Methods for producing stocks of recombinant AAV virions
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
US20050266024A1 (en) * 2002-03-19 2005-12-01 Powdermed Limited Adjuvant
CN100360558C (zh) * 2002-06-11 2008-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US7501503B2 (en) * 2002-12-31 2009-03-10 Mcgill University Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase
CA2539864A1 (en) 2003-09-24 2005-04-07 Oxxon Therapeutics Limited Hiv pharmaccines
US20050175627A1 (en) 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines

Also Published As

Publication number Publication date
TW200621806A (en) 2006-07-01
PE20060577A1 (es) 2006-08-07
KR20070041765A (ko) 2007-04-19
JP2014239687A (ja) 2014-12-25
CY1109667T1 (el) 2014-08-13
JP2011234722A (ja) 2011-11-24
RU2007104088A (ru) 2008-09-10
CA2575898C (en) 2015-09-29
PT1773999E (pt) 2009-12-16
US20100184836A1 (en) 2010-07-22
KR101501495B1 (ko) 2015-03-11
CA2575898A1 (en) 2006-02-09
EP1773999B1 (en) 2009-09-23
MY145614A (en) 2012-03-15
EP2130921B1 (en) 2013-11-20
EP1773999A2 (en) 2007-04-18
ES2334044T3 (es) 2010-03-04
ZA200700771B (en) 2009-04-29
GB0417494D0 (en) 2004-09-08
WO2006013106A3 (en) 2006-08-17
DK1773999T3 (da) 2010-01-18
ES2486669T3 (es) 2014-08-19
MA28983B1 (fr) 2007-11-01
AU2005268856A1 (en) 2006-02-09
RU2441878C2 (ru) 2012-02-10
IL207575A0 (en) 2011-07-31
CN102633866B (zh) 2015-04-15
EP2280073A3 (en) 2011-06-29
EP2130921A3 (en) 2010-03-03
WO2006013106A2 (en) 2006-02-09
AR080216A2 (es) 2012-03-21
MX2007001515A (es) 2007-09-07
US7612173B2 (en) 2009-11-03
ATE443769T1 (de) 2009-10-15
NZ552976A (en) 2010-01-29
BRPI0514108A (pt) 2008-05-27
JP5629647B2 (ja) 2014-11-26
AR050102A1 (es) 2006-09-27
SG155206A1 (en) 2009-09-30
IL180947A0 (en) 2007-07-04
EP2130921A2 (en) 2009-12-09
ES2445453T3 (es) 2014-03-03
CN101035897B (zh) 2012-02-01
JP2008507987A (ja) 2008-03-21
EP2280073A2 (en) 2011-02-02
AU2005268856B2 (en) 2012-05-24
TWI365191B (en) 2012-06-01
CN102633866A (zh) 2012-08-15
JP6007212B2 (ja) 2016-10-12
DE602005016810D1 (de) 2009-11-05
US20070243203A1 (en) 2007-10-18
NO20070988L (no) 2007-05-04
EP2280073B1 (en) 2014-06-11
HK1108168A1 (en) 2008-05-02
CN101035897A (zh) 2007-09-12
HRP20090678T1 (hr) 2010-01-31
PL1773999T3 (pl) 2010-02-26

Similar Documents

Publication Publication Date Title
HK1108168A1 (en) Vaccine for prevention and treatment of hiv-infection
PT1793855T (pt) Prevenção e tratamento de doença sinucleinopática e amiloidogénica
EP1753777A4 (en) METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING HIV INFECTION WITH TRIM5a
AU2003290548A8 (en) Prevention and treatment of synucleinopathic disease
HK1190084A1 (zh) 用於預防和治療補體相關紊亂的 多肽
EP1910829A4 (en) PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGENIC DISEASE
IL177914A0 (en) Use of indazolecarboxamide derivatives for the preparation of a medicament that is intended for the treatment and prevention of paludism
EP1796666A4 (en) METHOD AND COMPOSITIONS FOR TREATING HYPERLIPIDEMIA
ZA200803493B (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
IL178996A0 (en) Thienopyridinone compounds and methods of treatment
GB0610350D0 (en) prevention and/or treatment of neuodegenerative disorders
IL182436A0 (en) Thienopyridinone compounds and methods of treatment
ZA200701531B (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
EP1784221A4 (en) METHOD FOR THE TREATMENT AND PREVENTION OF INFECTIONS WITH ANTI-SELECTIN AGENTS
EP1817039A4 (en) TREATMENT AND PREVENTION OF EPILEPSY
IL187405A0 (en) Methods and compositions for the treatment of pain
EP1930017A4 (en) EFFECTIVE COMPOSITION FOR THE PREVENTION AND TREATMENT OF PATHOLOGY IN THE ADULT
GB2441094B (en) Methods for treatment and prevention of infection
PL1812797T3 (pl) Kompozycje i sposoby do leczenia chorób hiperproliferacyjnych i zapobiegania tym chorobom
ZA200710476B (en) Methods and compositions for the treatment of pain
GB201010682D0 (en) Methods for treatment and prevention of infection
GB0510257D0 (en) Methods for treatment and prevention of infection
GB0612749D0 (en) Treatment and/or prevention of pain
GB0313065D0 (en) Vaccine and therapeutic treatment
GB0414428D0 (en) Compounds and methods of treatment